BRPI0614810A2 - combinação de compostos orgánicos - Google Patents

combinação de compostos orgánicos

Info

Publication number
BRPI0614810A2
BRPI0614810A2 BRPI0614810-7A BRPI0614810A BRPI0614810A2 BR PI0614810 A2 BRPI0614810 A2 BR PI0614810A2 BR PI0614810 A BRPI0614810 A BR PI0614810A BR PI0614810 A2 BRPI0614810 A2 BR PI0614810A2
Authority
BR
Brazil
Prior art keywords
combination
organic compounds
compound
treating
preventing
Prior art date
Application number
BRPI0614810-7A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Paul W Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0614810A2 publication Critical patent/BRPI0614810A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAçãO DE COMPOSTOS ORGáNICOS. A invenção proporciona uma combinação farmacêutica que compreende: a) um composto de pirimidilaminobenzamida; e b) um composto de inibidor de HDAC, e um método para tratar ou prevenir uma doença proliferativa usando tal combinação.
BRPI0614810-7A 2005-08-11 2006-08-10 combinação de compostos orgánicos BRPI0614810A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70743605P 2005-08-11 2005-08-11
PCT/US2006/031563 WO2007022044A2 (en) 2005-08-11 2006-08-10 Combination of organic compounds

Publications (1)

Publication Number Publication Date
BRPI0614810A2 true BRPI0614810A2 (pt) 2009-08-04

Family

ID=37735081

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614810-7A BRPI0614810A2 (pt) 2005-08-11 2006-08-10 combinação de compostos orgánicos

Country Status (11)

Country Link
US (1) US20080200489A1 (pt)
EP (1) EP1915154A2 (pt)
JP (1) JP2009504674A (pt)
KR (1) KR20080044277A (pt)
CN (1) CN101282728A (pt)
AU (2) AU2006279781A1 (pt)
BR (1) BRPI0614810A2 (pt)
CA (1) CA2617979A1 (pt)
MX (1) MX2008001971A (pt)
RU (1) RU2008108911A (pt)
WO (1) WO2007022044A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
CA2753637A1 (en) * 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
AU2012319188B2 (en) * 2011-10-03 2016-11-24 Sloan-Kettering Institute For Cancer Research Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2015100363A1 (en) 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
JP6531312B2 (ja) * 2014-10-17 2019-06-19 東洋鋼鈑株式会社 Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006501267A (ja) * 2002-09-13 2006-01-12 バージニア コモンウェルス ユニバーシティー 白血病の処置のためのａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよびｂ）ヒストンデアセチラーゼインヒビターの組合せ剤
US20040127571A1 (en) * 2002-09-19 2004-07-01 University Of South Florida Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate

Also Published As

Publication number Publication date
EP1915154A2 (en) 2008-04-30
AU2006279781A1 (en) 2007-02-22
JP2009504674A (ja) 2009-02-05
CA2617979A1 (en) 2007-02-22
WO2007022044A3 (en) 2007-05-24
RU2008108911A (ru) 2009-09-20
CN101282728A (zh) 2008-10-08
MX2008001971A (es) 2008-03-26
WO2007022044A2 (en) 2007-02-22
US20080200489A1 (en) 2008-08-21
AU2010235917A1 (en) 2010-11-11
KR20080044277A (ko) 2008-05-20

Similar Documents

Publication Publication Date Title
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
BRPI0517887A (pt) combinações de inibidores de jaks
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
SV2009002899A (es) Diarilureas para el tratamiento de la hipertension pulmonar
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
BRPI0709769B8 (pt) implantes biodegradáveis para o tratamento de estados associados à dopamina
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001163A1 (es) Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
BRPI0614810A2 (pt) combinação de compostos orgánicos
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.